

Comparative Molecular Analysis and Antigenicity Prediction of an Outer Membrane Protein (ompC) of Non-typhoidal *Salmonella* Serovars Isolated from Different Food Animals in Lagos, Nigeria

Bioinformatics and Biology Insights
Volume 17: 1–11
© The Author(s) 2023
Article reuse guidelines:
sagepub.com/journals-permissions
DOI: 10.1177/11779322231176131



Morufat Yusuf¹, Abraham Ajayi², Utibeima Udo Essiet², Oyin Oduyebo³, Adeyemi Isaac Adeleye¹ and Stella Ifeanyi Smith^{2,4}

¹Department of Microbiology, University of Lagos, Akoka, Nigeria. ²Molecular Biology and Biotechnology Department, Nigerian Institute of Medical Research, Lagos, Nigeria. ³Department of Medical Microbiology, College of Medicine, University of Lagos, Idi-Araba, Nigeria.

⁴Department of Biological Sciences, Mountain Top University, Ibafo, Nigeria.

ABSTRACT: Non-typhoidal *Salmonella* (NTS) infections occur globally with high morbidity and mortality. The public health challenge caused is exacerbated by increasing rate of antibiotic resistance and absence of NTS vaccine. In this study, we characterized the outer membrane protein C (*OmpC*) serovars isolated from different food animals and predicted antigenicity. *ompC* of 27 NTS serovars were amplified by polymerase chain reaction (PCR) and sequenced. Sequence data were analysed and B-cell epitope prediction was done by BepiPred tool. T-cell epitope prediction was done by determining peptide-binding affinities of major histocompatibility complex (MHC) classes I and II using NetMHC pan 2.8 and NetMHC-II pan 3.2, respectively. *ompC* sequence analysis revealed conserved region among *ompCs* of *Salmonella* Serovars. A total of 66.7% of *ompCs* were stable with instability index value < 40 and molecular weight that ranged from 27745.47 to 32714.32 kDa. All *ompCs* were thermostable and hydrophilic with the exception of *S. Pomona* (14p) isolate that had *ompC* with GRAVY value of 0.028 making it hydrophobic. Linear B-cell epitope prediction revealed ability of *ompC* to elicit humoral immunity. Multiple B-cell epitopes that were exposed and buried were observed on several positions on the *ompC* sequences. T-cell epitope prediction revealed epitopes with strong binding affinity to MHC-I and -II. Strong binding to human leukocyte antigen (HLA-A) ligands, including HLA-A03:1; HLA-A24:02 and HLA-A26:01 in the case of MHC-I were observed. While binding affinity to H-2 IAs, H-2 IAq and H-2 IAu (H-2 mouse molecules) were strongest in the case of MHC-II. *ompCs* of NTS serovars isolated from different food animal sources indicated ability to elicit humoral and cell-mediated immunity. Hence, *ompCs* of NTS serovars are potential candidate for production of NTS vaccines.

KEYWORDS: Antigenicity, B-cell, outer membrane protein, *Salmonella*, T-cell

RECEIVED: February 2, 2023. **ACCEPTED:** April 29, 2023.

TYPE: Original Research Article

FUNDING: The author(s) received no financial support for the research, authorship, and/or publication of this article.

DECLARATION OF CONFLICTING INTERESTS: The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

CORRESPONDING AUTHOR: Stella Ifeanyi Smith, Molecular Biology and Biotechnology Department, Nigerian Institute of Medical Research, Lagos, Nigeria. Email: stellaismith@yahoo.com

Introduction

Salmonella enterica remains a pathogen of concern globally, since it continually causes infections that results in high morbidity and mortality.¹ Depending on clinical outcomes, serotypes of *Salmonella* are broadly grouped into typhoidal *Salmonella* (TS) and non-typhoidal *Salmonella* (NTS).² While TS serovars are human restricted, NTS serovars cause infection in birds, mammals and humans.³ Although NTS serovars cause self-limiting diarrhoea in individuals, infection in infants and immunocompromised persons could be severe or fatal.⁴ It is estimated that NTS serovars cause 93 million infections with 155 000 associated deaths per year globally.⁵ In 2022 alone, several outbreaks of NTS infections have been reported in Europe (*S. Enteritidis* and *S. Typhimurium*) and the United States (*S. Enteritidis*, *S. Typhimurium*, *S. Hadar*, *S. Infantis*, *S. Indiana*, 14,[5], 12:1 and *S. Mbandaka*) resulting in hospitalization and deaths.^{6–9} Treatment of bacterial infections, including NTS infections are becoming difficult as a result of antimicrobial resistance (AMR). The World Health Organization (WHO) has categorized fluoroquinolone (FQ)-resistant *Salmonella* spp. as priority pathogen urgently in need of new antibiotics.¹⁰ This

underscores the need for NTS vaccines. There is currently no NTS vaccine in use, however, several vaccine candidates, including live-attenuated, glycoconjugate, outer membrane vesicle vaccines and many more are in various stages of development and clinical trials.¹¹ *Salmonella* live-attenuated vaccines (SLAVs) have the potential to elicit both humoral and cell-mediated responses, however, their safety in immunocompromised individuals at high risk of coming down with invasive non-typhoidal *Salmonella* (iNTS) has been brought to question.⁵ Hence, the need to explore other cell components of NTS serovars for vaccine production is imperative. Returning to normal life during this COVID-19 pandemic could in part be attributed to the prompt production of vaccines especially the mRNA vaccine that initiates the production of viral spike proteins that in turn elicit immune response to severe acute respiratory syndrome coronavirus 2 (SARS-Cov-2) virus.¹² The outer membrane proteins (omps) of *Salmonella*, such as *ompC*, *ompD* and *ompF*, are known antigens that are highly immunogenic and elicit cellular immunity and efficient protective antibody.¹³ *OmpCs* of *Salmonella* have been indicated as a potential broad spectrum *Salmonella* vaccine candidate as several highly conserved amino



Creative Commons Non Commercial CC BY-NC: This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (<https://creativecommons.org/licenses/by-nc/4.0/>) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (<https://us.sagepub.com/en-us/nam/open-access-at-sage>).

acid sequences located in the transmembrane β -sheet have been identified in both typhoidal and non-typhoidal serovars.¹³ Carreño et al¹⁴ in a study demonstrated that OmpC of *S. Typhi* elicited specific B-cell responses and polyfunctional CD4⁺ T-cell responses that evolved over a period of 2 months post-administration of live-attenuated vaccine. Similarly, OmpC of *S. Typhimurium* has been shown to elicit cell-mediated and humoral immune responses that conferred absolute protection against *S. Typhimurium* in rats.¹⁵ Although omps of *Salmonella* are promising vaccine candidates, available data tend to centre majorly on *S. Typhimurium* that is just one among other numerous NTS serovars that have been implicated in outbreaks and invasive infections. Questions on spectrum of activity (broad spectrum) of NTS omps base vaccines have been raised. For instance, ompD has been shown to mediate immune response that limits clinical outcome of invasive *S. Typhimurium* infection.¹¹ However, Ashton et al¹⁶ reported the absence of ompD locus in *S. Typhimurium* (ST313) strain U60 isolated in the United Kingdom. The need to study the omps of other NTS, including rear serovars for vaccine prospect is therefore imperative. This study aimed to molecularly characterize OmpC of NTS serovars isolated from different sources and predict their antigenicity.

Materials and Methods

Salmonella isolates

Thirty previously isolated *Salmonella* Serovars from animal sources (chicken, sheep and cattle) stored in the stock culture of Molecular Epidemiology Unit of the Molecular Biology and Biotechnology Department of Nigerian Institute of Medical Research (NIMR) Yaba Lagos were retrieved. To resuscitate the isolates, a loop full of the isolates in glycerol stock were inoculated into 1 mL of brain heart infusion broth (Oxoid, Basingstoke, UK) and incubated for 18 hour at 37°C after which they were streaked on nutrient agar plate and incubated for 24 hours at 37°C. Isolates were then stored in agar slants for further use.

DNA Extraction

Isolates were inoculated into 1 mL of brain heart infusion broth (Oxoid, Basingstoke, UK) and incubated for 18 hours at 37°C. Cells were harvested by centrifuging at 14 rpm for 3 minutes and supernatant was discarded retaining the cell pellet. Genomic DNA was extracted with bacterial genomic DNA isolation Kit (NorgenBiotek Corp., Canada) according to the manufacturer's instructions. Two hundred and fifty microliter of re-suspension solution A was added to cell pellet and vortexed to make a cell suspension to which 12 μ L of lysozyme (400 mg/mL) was added and mixed. Then, 250 μ L of lysis buffer P and 12 μ L of proteinase K were added to the cell suspension vortexed and incubated at 37°C for 2 hours. Five hundred microliter was added to the lysate and mixed

well with gentle vortexing after which 500 μ L of 100% ethanol was added and mixed again by gentle vortexing. Spin columns were assembled into which lysate mixtures were dispensed and centrifuged at 14 000 rpm for 1 minute. After centrifugation, flow-through was discarded and spin column was reassembled. Five hundred microliter of wash solution A was added to spin column and centrifuged for 1 minute at 14 000 rpm. Flow-through was discarded and the washing process was repeated once more. After the second wash and discarding of the flow-through, the column was centrifuged for 2 minutes to ensure the column was thoroughly dried. The spin column was reassembled with a new 1.7 mL collection tube and 200 μ L of elution buffer B was added to the centre of the column which was then centrifuged for 2 minute at 14 000 rpm and pure genomic DNA obtained was stored at -20°C for further use.

Detection and Sequencing of ompC

Salmonella ompC gene was amplified by PCR using primer set F-ATGAAAGTTAAAGTACTGTCCCTC and R-TTAGA ACTGGTAAACCAGACCC.¹⁷ A 30 μ L PCR mix was used. The reaction mix contained 16.2 μ L nuclease-free water, 0.9 μ L forward primer, 0.9 μ L reverse primer, 6 μ L DNA template and 6 μ L of 5X PCR Master Mix (Solis BioDyne, Estonia). PCR programming parameter consisted of initial DNA denaturation at 95°C for 5 minutes, followed by 30 cycles of denaturation at 95°C for 30 seconds, annealing at 58°C for 40 seconds and extension at 72°C for 2 minutes, followed by a final extension at 72°C for 10 minutes. Electrophoresis was done to visualize amplicons. Gel electrophoresis was ran at 100 V for 60 minutes and visualized under a trans-illuminator (Clever Scientific Ltd). A 100bp DNA ladder (Solis BioDyne, Estonia) was used as a molecular weight marker. Fifteen microliter of PCR products, and 10 μ L of forward and reverse primers were aliquoted into a micro-centrifuge tube and sent to Inqaba Biotec, South Africa, for Sanger sequencing. Sequences obtained in this study have been deposited in the National Centre for Biotechnology Information (NCBI) database with accession numbers ON190078–ON190104.

Comparative Analysis of ompC Gene Sequences and Prediction of Antigenicity

Protein sequence analysis and phylogenetic tree construction

Nucleotide sequences of *ompC* were base called on Bioedit software¹⁸ and exported as FASTA to note pad. The Basic Local Alignment Search Tool (BLAST) analysis was done on NCBI database (<https://blast.ncbi.nlm.nih.gov/Blast.cgi>) to determine sequence homology with reference sequences. Nucleotide sequences were translated to amino acid sequences using the sorted six-frame translation tool of




Figure 1. Gel image of amplified *ompC* gene in *Salmonella* isolates. Lanes 1–17 positive *ompC* 1103bp bands. Lane M indicated 100 bp molecular maker; lane N, negative control; lane P, positive control.

Bioedit software and BLAST analysis was done on UniProt database (<https://www.uniprot.org/blast>) to confirm protein identity. Multiple sequence alignment was done using CLUSTALW and phylogenetic tree was constructed using the maximum likelihood joining tree in MEGA 11.0 software¹⁹ and variation were analysed. Protein 3D structure of *ompC* was determined from the PDBsum pictorial database in the protein data bank (<http://www.ebi.ac.uk/thornton-srv/databases/cgi-bin/pdbsum>).

Prediction of antigenicity

Properties of proteins were determined using ProtParam tool on the ExPASy platform and properties, such as number of amino acids, molecular weight, instability index, aliphatic index and theoretical isoelectric point (pI) was recorded. B-cell epitope prediction to determine B-cell epitope regions of *ompC* protein was done with BepiPred prediction tool on the cbs.dtu.dk server (<http://www.cbs.dtu.dk/services/BepiPred/>).²⁰ Scores of epitopes were recorded and peptides with 10 or more amino acids in length were considered as good B-cell epitopes. T-cell epitope prediction was done by determining peptide-binding affinities of MHC classes I and II by calculating epitope database analysis and ranking them according to their percentile using NetMHCpan 2.8 (<https://services.healthtech.dtu.dk/service.php?NetMHCpan-2.8>) and NetMHCIIpan 3.2 (<https://services.healthtech.dtu.dk/service.php?NetMHCIIpan-3.2>) servers for MHC-I and -II, respectively.²¹ For MHC-I, affinity threshold for strong binding peptides was set at 5000 and affinity threshold for weak binding

peptides was set at 500 000. While rank threshold for strong binding peptides was set at 0.500 and for weak binding peptides 2.00. On the other hand, rank threshold for strong and weak binding peptides for MHC-II was set at 2 and 10, respectively.

Results

Protein sequence analysis and properties of protein

ompC was detected in all (100%) the *Salmonella* isolates as the *ompC* gene of 1103bp gene was amplified as shown in Figure 1. However, *ompC* of three of the *Salmonella* isolates failed sequencing quality control (QC) and could not be sequenced. *ompC* sequence analysis from multiple sequence alignment showed conserved regions among *ompCs* of *Salmonella* Serovars as shown in Figure 2. However, phylogenetic analysis of protein sequence revealed that three major clades (**A**, **B** and **C**) were formed by various serovars. Some *Salmonella* isolates that were the same serovar clustered with some other serovars; 18P_ *S.* Gera (a dominant serovar in this study) clustered with *S.* Enteritidis in clade **B** that comprised *S.* Ealing, *S.* Muenster, *S.* Hadar, and *S.* Blockely as shown in Figure 3. Similarly, 31P_ *S.* Gera, 33P_ *S.* Gera, 23P_ *S.* Gera and 27P_ *S.* Gera clustered with other *Salmonella* Serovars in clade **C**.

Table 1 shows the physicochemical properties of *ompCs* of various *Salmonella* Serovars. Total number of negatively charged residues (Asp + Glu) in some of the *ompCs* of some of the serovars were low with concomitant high instability index resulting in unstable proteins. However, 66.7% of the proteins were stable with instability index values < 40. Molecular weight of *ompCs* ranged from 27745.47 to




Figure 2. Multiple sequence alignment of *ompC* protein sequence showing conserved glycine (G) and proline (P) among *Salmonella* Serovars.




Figure 3. Phylogenetic analysis of *ompC* protein sequences of *Salmonella* Serovars. Three main clades **A**, **B** and **C** were formed.

Table 1. Various properties of ompCs of *Salmonella* Serovars, including number of amino acids, molecular weight, theoretical pI, instability index, aliphatic index and hydropathicity.

ID	NO. OF AA	MW	THEORETICAL PI	TOTAL NUMBER OF NEG. CHARGED RESIDUES	TOTAL NUMBER OF POS. CHARGED RESIDUE	INSTABILITY INDEX	ALIPHATIC INDEX	HYDROPATHICITY
3p	298	32714.32	9.27	22	31	29.70—stable	62.18	-0.605
4p	287	30907.14	9.10	22	28	19.55—stable	61.22	-0.530
5p	281	29990.89	8.90	21	25	13.28—stable	61.10	-0.555
6p	288	31225.62	6.57	25	24	15.48—stable	66.42	-0.528
8p	259	27745.47	9.16	21	26	17.22—stable	54.98	-0.699
9p	280	30521.66	9.14	23	29	21.88—stable	56.82	-0.695
10p	276	31678.89	11.81	11	54	73.60—unstable	81.34	-0.534
11p	286	29869.38	10.04	11	34	40.30—unstable	72.76	-0.107
12p	287	30375.33	8.84	22	26	20.61—stable	57.11	-0.607
13p	288	31484.89	9.24	21	29	29.46—stable	55.21	-0.645
14p	290	30744.08	10.45	10	36	44.63—unstable	80.48	0.028
15p	290	31311.76	8.70	20	24	23.52—stable	59.52	-0.524
16p	293	31176.08	9.90	14	36	42.26—unstable	77.41	-0.080
17p	291	31192.34	7.12	23	23	18.73—stable	66.08	-0.457
18p	287	30102.47	9.50	16	31	32.51—stable	73.90	-0.091
19p	290	31524.47	9.28	19	26	23.35—stable	74.34	-0.302
20p	293	31792.40	8.89	23	29	22.99—stable	64.91	-0.507
21p	290	31975.64	8.53	21	25	28.38—stable	65.62	-0.477
22p	287	32119.06	11.83	11	49	61.74—unstable	80.00	-0.485
23p	293	32256.94	8.76	24	29	23.43—stable	66.55	-0.481
25p	276	30675.35	9.74	19	33	43.23—unstable	60.76	-0.686
26p	283	31973.91	11.94	12	60	69.54—unstable	75.90	-0.705
27p	288	31388.26	8.76	22	26	23.90—stable	64.06	-0.370
28p	293	32016.52	8.99	23	29	17.04—stable	66.59	-0.539
31p	286	31239.30	10.48	12	44	40.36—unstable	67.27	-0.324
32p	282	32250.85	11.86	8	53	61.62—unstable	74.79	-0.513
33p	285	31457.03	9.58	21	34	33.15—stable	56.49	-0.715

Abbreviations: AA, amino acid; MW, molecular weight; pI, isoelectric point.

Table 2. Number of predicted B-cell epitopes and surface orientation in *Salmonella* Serovars.

S/N	CODE	SALMONELLA SEROVARS	NO. OF EPITOPES	EXPOSED (%)	BURIED (%)
1	3P	S. Anatum	166	149 (89.76)	31 (18.67)
2	4P	S. Anatum	218	151 (69.27)	67 (30.73)
3	5P	S. Ealing	141	85 (60.28)	56 (39.72)
4	6P	S. Muenster	200	145 (72.50)	55 (27.50)
5	8P	S. Blockley	180	123 (68.33)	57 (31.66)
6	9P	S. Ealing	145	103 (71.03)	42 (28.97)
7	10P	S. Blockley	149	91 (61.07)	58 (38.93)
8	11P	S. Ealing	204	81 (39.71)	123 (60.29)
9	12P	S. Enteritidis	212	142 (66.98)	70 (33.02)
10	13P	S. Gera	189	137 (72.49)	52 (27.51)
11	14P	S. Pomona	122	77 (63.11)	45 (36.89)
12	15P	S. Muenster	205	136 (60.34)	69 (33.66)
13	16P	S. Blockley	168	110 (65.48)	58 (34.52)
14	17P	S 9:1, w:e,n,x	142	100 (70.42)	42 (29.58)
15	18P	S. Gera	134	88 (65.67)	46 (34.33)
16	19P	S. Pomona	141	91 (64.54)	50 (35.46)
17	20P	S. Gera	211	149 (70.62)	62 (29.38)
18	21P	S. Enteritidis	188	141 (75.00)	47 (25.00)
19	22P	S. Anatum	206	146 (70.87)	60 (29.13)
20	23P	S. Gera	151	102 (67.55)	49 (32.45)
21	25P	S. Muenster	181	119 (65.75)	62 (34.25)
22	26P	S. Blockley	199	114 (57.29)	85 (42.71)
23	27P	S. Gera	149	99 (66.44)	50 (33.56)
24	28P	9:1, w:e,n,x	140	95 (67.86)	45 (32.14)
25	31P	S. Gera	144	90 (62.50)	54 (37.50)
26	32P	S. Hadar	171	96 (56.14)	75 (43.86)
27	33P	S. Gera	157	99 (63.06)	58 (36.94)

MHC-II

Predicted MHC–peptide-binding affinity of the various H-2 mouse molecules revealed varied numbers of strong and weak binders. Molecules H-2 IAs had a total of 371 strong binders among *Salmonella* servers followed by molecule H-2 IAq with 348 strong binders and H-2 I Au with a total of 284 strong binders among the serovars (Figure 5). A total of 246 and 283 strong binders were detected in molecule H-2 IE d and H-2 IE k, respectively, among the serovars (Figure 6). The least number of binders among the serovars was found in the H-2 IA k molecule with 166 strong binders as shown in Figure 7.

Discussion

The genus *Salmonella* consist of six subspecies with over 2600 phenotypically, ecologically and genetically diverse serovars.²² All NTS serovars in this study isolated from different food animal sources were positive for OmpC. This implies that OmpC is largely distributed among *Salmonella* Serovars. Jawad and Al-Charrakh²³ similarly reported the PCR amplification of OmpC in all *Salmonella* strains isolated from human and animal samples in Iraq. Serovars in this study showed genetic interrelatedness with similar serovars clustering with unrelated serovars inferred from phylogenetic analysis of OmpC sequences. Although variation existed in protein sequences of serovars there was a high level of sequence homology with

Table 3. Affinity and ranks of strongest binding representatives of peptides to various alleles of HLA-A and HLA-B ligands, including total numbers of 9mers peptides of various *Salmonella* isolates.

ID	TOTAL NUMBERS OF 9MERS PEPTIDES	VARIOUS ALLELES OF HLA-A AND HLA-B LIGANDS												TSB	TWB						
		HLA-A01:01		HLA-A02:01		HLA-A03:01		HLA-A24:02		HLA-A26:01		HLA-B07:02				HLA-B08:01		HLA-B27:05			
		1-LOG50K	RANK	1-LOG50K	RANK	1-LOG50K	RANK	1-LOG50K	RANK	1-LOG50K	RANK	1-LOG50K	RANK			1-LOG50K	RANK	1-LOG50K	RANK		
3P	290	-	-	-	-	0.6668	0.175	0.6296	0.3	-	-	-	-	0.8058	0.075	0.7664	0.025	0.6535	0.1	14	51
4P	277	-	-	-	-	0.6668	0.175	-	-	-	-	-	-	0.678	0.3	0.7319	0.05	0.7246	0.025	11	31
5P	274	0.7769	0.025	-	-	0.678	0.15	0.6296	0.3	0.7846	0.05	-	-	-	-	-	-	-	-	4	16
6P	273	-	-	0.794	0.4	-	-	0.7432	0.075	-	-	-	-	0.7886	0.1	0.7312	0.05	0.7308	0.025	17	21
8P	246	-	-	-	-	0.6369	0.25	-	-	-	-	-	-	-	-	0.5631	0.4	0.695	0.05	16	35
9P	268	-	-	0.8311	0.2	0.6949	0.125	-	-	-	-	-	-	0.8384	0.05	0.6422	0.15	0.7689	0.01	11	30
10P	278	0.605	0.125	0.8672	0.1	0.678	0.15	-	-	0.6293	0.125	-	-	-	-	0.5495	0.4	0.6154	0.175	8	22
11P	279	0.5035	0.25	0.794	0.4	0.697	0.1	0.7164	0.125	0.6281	0.1	0.0221	0.2	-	-	-	-	0.7033	0.05	11	23
12P	274	-	-	-	-	0.6256	0.3	-	-	0.7224	0.075	-	-	-	-	0.7319	0.05	0.6625	0.075	10	35
13P	278	0.507	0.25	-	-	0.6668	0.175	-	-	0.5779	0.2	0.8113	0.05	0.6225	0.2	0.6225	0.2	0.695	0.05	14	42
14P	285	0.5035	0.25	0.9027	0.05	0.7177	0.075	0.6469	0.25	0.7839	0.05	0.6009	0.5	-	-	-	-	-	-	6	24
15P	281	0.5096	0.2	-	-	-	-	-	-	0.6116	0.15	0.852	0.025	0.6772	0.1	0.6772	0.1	0.7689	0.01	11	25
16P	286	0.7559	0.025	-	-	0.678	0.15	0.5495	0.5	0.7486	0.05	-	-	-	-	0.7044	0.075	0.6767	0.075	7	35
17P	284	0.7559	0.025	-	-	0.7177	0.075	0.616	0.3	0.7486	0.05	0.1023	0.5	-	-	-	-	0.5212	0.5	7	25
18P	280	-	-	0.8672	0.1	0.6541	0.2	0.6176	0.3	0.4662	0.5	0.6591	0.4	-	-	-	-	0.7689	0.01	6	25
19P	282	0.8541	0.01	-	-	0.7177	0.075	0.616	0.3	0.7486	0.5	0.0463	0.05	0.6084	0.25	0.6084	0.25	0.5228	0.5	10	29
20P	283	-	-	0.912	0.025	0.6668	0.175	0.6474	0.25	-	-	-	-	0.7886	0.1	0.7177	0.075	0.75	0.01	17	47
21P	279	-	-	-	-	-	-	-	-	-	-	-	-	0.0735	0.3	0.5448	0.4	0.7689	0.01	8	25
22P	280	-	-	-	-	0.6377	0.25	-	-	-	-	-	-	0.8672	0.025	0.7665	0.025	0.6645	0.075	16	33
23P	286	0.8541	0.01	0.8405	0.175	0.726	0.075	0.6724	0.175	0.6651	0.1	-	-	-	-	0.86	0.01	0.6725	0.075	19	16
25P	263	-	-	-	-	-	-	-	-	-	-	-	-	0.8727	0.025	0.5389	0.5	0.6	0.2	6	25
26P	276	-	-	-	-	0.7212	0.075	-	-	-	-	-	-	0.7431	0.15	0.6644	0.125	0.7074	0.05	12	26
27P	281	0.5632	0.15	-	-	0.7013	0.1	-	-	0.6293	0.125	0.7997	0.015	0.6542	0.125	0.6542	0.125	-	-	5	27
28P	286	0.5196	0.2	-	-	0.7177	0.075	0.5584	0.5	0.713	0.075	-	-	-	-	-	-	0.5904	0.25	8	24
31P	278	-	-	-	-	0.7338	0.05	-	-	0.6077	0.175	0.6246	0.5	0.6419	0.15	0.6419	0.15	0.6734	0.075	3	24
32P	281	-	-	0.794	0.4	-	-	0.5517	0.5	0.4662	0.5	0.8384	0.05	0.6422	0.15	0.6422	0.15	0.7517	0.01	6	31
33P	278	0.5196	0.2	-	-	0.7177	0.075	0.801	0.05	0.5821	0.2	0.6928	0.25	0.7995	0.025	0.7995	0.025	0.6436	0.1	11	24

Abbreviations: 1-log50k, prediction score of affinity; 9mers, protein fragments of length 9; Rank, % rank; TSB, total strong binders; TWB, total weak binders.




Figure 5. Predicted MHC-II-peptide-binding affinity of H2-IAs, H2-IAq and H2-IAu showing numbers of strong and weak binders.




Figure 6. Predicted MHC-II-peptide-binding affinity of H2-IEd and H2-IEk showing numbers of strong and weak binders.




Figure 7. Predicted MHC-II-peptide-binding affinity of H2-IAb, H2-IAd and H2-IAk showing numbers of strong and weak binders.

identified conserved regions. Valero-Pacheco et al¹³ in a previous study have reported highly conserved amino acid sequences of OmpC among both TS and NTS serovars. The need for prospecting for NTS vaccine is important considering the increasing number of iNTS infections coupled with the high burden of AMR.²⁴ Vaccine potential of the OmpC of NTS as earlier highlighted tends to be a resource that needs to be explored and exploited to solve the problem. Beyond being conserved among *Salmonella* Serovars,²⁵ OmpC of NTS possess physicochemical parameters that make them ideal antigens. Functional and physicochemical properties of vaccine antigens are core determinants of the level of antigen-adjuvant interaction and vaccine response.²⁶ In this study, a large percentage of the OmpCs of serovars, including *S. Enteritidis* were stable with instability index of < 40. They had aliphatic index that indicated they were thermostable and GRAVY values that showed they were hydrophilic. Rabbani et al²⁷ in a previous study have demonstrated the conformation and thermostability of *omp* of *S. Typhi* to different pH conditions. Similar physicochemical properties have been reported for *ompC* and *ompF* of *S. Typhimurium* by Jha et al²⁸ and Soman et al,²⁹ respectively.

Functional properties of OmpC as an ideal vaccine antigen have been demonstrated in previous studies. However, most studies have only evaluated and reported on the OmpCs of *S. Typhimurium* and *S. Typhi*.^{13-15,28} Concerns have been raised on the limitation of the use of certain *omps*, such as

ompD, as broad spectrum vaccine against NTS infections.¹¹ *ompCs* of *Salmonella* Serovars investigated in this study all possessed linear B-cell epitopes on several positions with majority exposed capable of evoking immune response. This is in line with the findings of Jha et al²⁸ who reported B-cell epitopes with antigenic index of 1.7 from the mapping of the OmpC of *S. Typhimurium*. Studies have highlighted the importance of the accessibility of epitopes to MHC-I and MHC-II to elicit optimal immune response.³⁰ Immunogenic potential of OmpC for MHC-I predicted in this study showed strong binders with more affinity to HLA-B ligand. On the other hand immunogenic potential of OmpC for MHC-II showed strong binding with high preference to H-2 IAs a variant of H-2 mouse molecule. Valero-Pacheco et al¹³ in their study reported conserved OmpC amino acid sequences with immunogenic potential for MHC-II binding.

Conclusion

In conclusion, findings from our study revealed that OmpC of various *Salmonella* Serovars possessed B-cell and T-cell epitopes that have the potential of evoking immune response. Hence, OmpC of these serovars can be considered for design of broad spectrum vaccine against NTS.

Author Contributions

MY, AA and EUU contributed to data collection; MY, AA and EUU contributed to data analysis and preparation of draft;

AA, AIA and SIS contributed to conceptualization of study; and OO, AIA and SIS supervision and correction of draft. All authors read and approved final draft.

REFERENCES

1. Woh PY, Yeung MPS, Nelson EAS, Goggins WB. Risk factors of non-typhoidal *Salmonella* gastroenteritis in hospitalized young children: a case-control study. *BMJ Paediatr Open*. 2021;5:e000898. doi:10.1136/bmjpo-2020-000898.
2. Haeusler GM, Curtis N. Non-typhoidal *Salmonella* in children: microbiology, epidemiology and treatment. *Adv Exp Med Biol*. 2013;764:13-26. doi:10.1007/978-1-4614-4726-9_2.
3. Wemyss MA, Pearson JS. Host cell death responses to non-typhoidal *Salmonella* infection. *Front Immunol*. 2019;10:1758.
4. Rana S, Maurya S, Chadrasekhar H, Srikanth CV. Molecular determinants of peaceful coexistence versus invasiveness of non typhoidal *Salmonella*: implications in long-term side-effects. *Mol Aspects Med*. 2021;81:100997. doi:10.1016/j.mam.2021.100997.
5. Balasubramanian R, Im J, Lee JS, et al. The global burden and epidemiology of invasive non-typhoidal *Salmonella* infections. *Hum Vaccin Immunother*. 2019;15:1421-1426.
6. European Centre for Disease Prevention Control, European Food Safety Authority. Multi-country outbreak of *Salmonella* enteritidis sequence type (ST)11 infections linked to eggs and egg products. *Joint ECDC-EFSA Rap Outb Assess* 2022;19:7180E. doi:10.2903/sp.efsa.2022.EN-7180.
7. Lesley L, Maria PG, Ann H, et al. Investigation of an international outbreak of multidrug-resistant monophasic *Salmonella* Typhimurium associated with chocolate products, EU/EEA and United Kingdom, February to April 2022. *Euro Surveill*. 2022;27:pil2200314. doi:10.2807/1560-7917.ES.2022.27.15.2200314.
8. Centers for Disease Control and Prevention. Investigation details: *Salmonella* outbreak linked to backyard poultry. Centers for Disease Control and Prevention. 2022. <https://www.cdc.gov/salmonella/backyardpoultry-06-22/details.html>.
9. Opegard SJ, Bethke AR, Davy BA, Johnson AE, Daniel JL, Holmes SE. Outbreak of *Salmonella* enteritidis at a correctional facility using mechanically separated chicken: Nebraska. *MMWR* 2022;71:908-909.
10. Tacconelli E, Carrara E, Savoldi A, et al. Discovery, research, and development of new antibiotics: the WHO priority list of antibiotic-resistant bacteria and tuberculosis. *Lancet Infect*. 2017;18:318-327. doi:10.1016/S1473-3099(17)30753-3.
11. Piccini G, Montomoli E. Pathogenic signature of invasive non-typhoidal *Salmonella* in Africa: implications for vaccine development. *Hum Vaccin Immunother*. 2020;16:2056-2071.
12. Watson OJ, Barnsley G, Toor J, Hogan AB, Winskill P, Ghani AC. Global impact of the first year of COVID-19 vaccination: a mathematical modeling study. *Lancet*. 2022;22:1293-1302.
13. Valero-Pacheco N, Blight J, Aldapa-Vega G, et al. Conservation of the OmpC porin among typhoidal and non-typhoidal *Salmonella* Serovars. *Front Immunol*. 2020;10:2966. doi:10.3389/fimmu.2019.02966.
14. Carreño JM, Perez-Shibayama C, Gil-Cruz C, et al. Evolution of *Salmonella* typhi outer membrane protein-specific T and B cell responses in humans following oral Ty21a vaccination: a randomized clinical trial. *PLoS ONE*. 2017;12:e0178669. doi:10.1371/journal.pone.0178669.
15. Hamid N, Jain SK. Characterization of an outer membrane protein of *Salmonella enterica* serovar Typhimurium that confers protection against typhoid. *Clin Vaccine Immunol*. 2008;15:1461-1471.
16. Ashton PM, Owen SV, Kaindama L, et al. Public health surveillance in the UK revolutionises our understanding of the invasive *Salmonella* Typhimurium epidemic in Africa. *Genome Med*. 2017;9:92. doi:10.1186/s13073-017-0480-7.
17. Kim SW, Lee JS, Park SB, et al. The importance of porins and β -lactamase in outer membrane vesicles on the hydrolysis of β -lactam antibiotics. *Int J Mol Sci*. 2020;21. doi:10.3390/ijms21082822.
18. Hall TA. BioEdit: a user-friendly biological sequence alignment editor and analysis program for Windows 95/98/NT. *Nucleic Acids Symp Ser*. 1999;41:95-98.
19. Tamura K, Stecher G, Kumar S. MEGA11: molecular evolutionary genetics analysis version 11. *Mol Biol Evol*. 2021;38:3022-3027. doi:10.1093/molbev/msab120.
20. Jespersen MC, Peters B, Nielsen M, Marcatili P. BepiPred-2.0: improving sequence-based B-cell epitope prediction using conformational epitopes. *Nucleic Acids Res*. 2017;45:W24-W29. doi:10.1093/nar/gkx352.
21. Jensen KK, Andreatta M, Marcatili P, et al. Improved methods for predicting peptide binding affinity to MHC class II molecules. *Immunology*. 2018;154:394-406. doi:10.1111/imm.12889.
22. Pulford CV, Wenner N, Redway ML, et al. The diversity, evolution and ecology of *Salmonella* in venomous snakes. *PLoS Negl Trop Dis*. 2019;13:e0007169. doi:10.1371/journal.pntd.0007169.
23. Jawad AA, Al-Charrakh AH. Outer membrane protein C (ompC) gene as the target for diagnosis of *Salmonella* species isolated from human and animal sources. *Avicenna J Med Biotechnol*. 2016;8:42-45.
24. Gilchrist JJ, MacLennan CA. Invasive nontyphoidal *Salmonella* disease in Africa. *Ecosal Plus*. 2019;8:e0007. doi:10.1128/ecosalplus.ESP-0007-2018.
25. Saxena MK, Kumar R, Bhatt P, Saxena MK. Immunogenic outer membrane proteins (Omps) of *Salmonella*: potential candidate for sub-unit vaccine. *Viral Immunol J*. 2017;1:000109.
26. AK Dey, Malyala P, Singh M. Physicochemical and functional characterization of vaccine antigens and adjuvants. *Expert Rev Vaccines*. 2014;13:671-685.
27. Rabbani G, Kaur J, Ahmad E, Khan RH, Jain SK. Structural characteristics of thermostable immunogenic outer membrane protein from *Salmonella enterica* serovar Typhi. *Appl Microbiol Biotechnol*. 2014;98:2533-2543.
28. Jha R, Kumar A, Saxena A, Tamuly S, Saxena MK. Cloning, sequencing and in silico analysis of Omp C of *Salmonella* Typhimurium. *ISRN Vet Sci*. 2012;2012:512848-512847. doi:10.5402/2012/512848.
29. Soman N, Prejit Pratheesh PT, Mahesh SH, Vinod VK. Cloning, sequencing and in silico characterization of OmpF protein of *Salmonella* Typhimurium for its immune potential. *Int J Curr Microbiol App Sci*. 2018;7:1991-2001.
30. Hammed- Akanmu M, Mim M, Osman AY, et al. Designing a multi-epitope vaccine against *Toxoplasma gondii*: an immunoinformatics approach. *Vaccines*. 2022;10:1389. doi:10.3390/vaccines10091389.